ABBV-3373
Based on 1 Customer Validation
ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC). ABBV-3373 consists of a humanized TNF antibody Adalimumab (HY-P9908) conjugated to a glucocorticoid receptor agonist (HY-148436). ABBV-3373 can be used for the research of rheumatoid arthritis.
For research use only. We do not sell to patients.
- Purity: 98.78%
-
Storage:
-80°C, protect from light
Biological Activity
The ABBV-3373 surrogate (3-10 mg/kg; single administration) inhibits FITC-induced ear swelling by 55-88% in the Mus musculus contact hypersensitivity model, with minimal effects on systemic glucocorticoid biomarkers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1 (collagen-induced arthritis model)[1]
-
Dosage:10 mg/kg (DAR4 ADC)
-
Administration:i.p.; single dose
-
Result:Achieved 98% inhibition of paw swelling AUC.
Maintained paw swelling reduction for > 30 days post-dose.
-
Animal Model:unspecified[1]
-
Dosage:10 mg/kg; 3 mg/kg
-
Administration:single dose (prior to sensitization)
-
Result:Inhibited ear swelling by 88%, plasma corticosterone by 15%, and plasma P1NP by 19% (at 10 mg/kg).
Inhibited ear swelling by 55%, plasma corticosterone by 6%, and caused a -16% change (increase) in plasma P1NP (at 3 mg/kg).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[ABBV-3373]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)